Author: Yaell Purple

Categories

• News and Events
  • Events
  • News
• Publications
  • CM-24
  • more about CM-24
  • more about NT-219
  • NT-219

Posts

• Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
• Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
• Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
• Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.
• Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023
• CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells
• Purple Biotech to participate and Present at the Jefferies London Healthcare Conference
• Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis 
• Purple Biotech to participate in a leadership call by Chardan Capital Markets LLC. – Click here to replay
• Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors